DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for MALT lymphoma — screening already-approved drugs against its 11-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMALT lymphoma maps to a 11-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
approvedThalidomideApproved drug
Structures already discussed alongside malt lymphoma in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
Cereblon isoform 4 from Magnetospirillum gryphiswaldense — Thalidomide has a real, experimentally solved structure in complex with this target (PDB 5AMH, 1.2 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet ef2drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5AMH · 1.2 Å · ligand Thalidomide (EF2). Experimental structure, not a prediction.
What the evidence adds up to
In a 1998 retrospective study of 60 patients with gastric lymphoma treated by radical gastrectomy alone, a 5-year survival rate of greater than 95% was attained for MALT lymphoma and for true stage IE lymphoma diagnosed after systematic lymphadenectomy. Low histopathologic grade was associated with a significantly lower incidence of nodal metastasis and less extensive gastric wall infiltration despite larger tumour size. The authors concluded that surgery alone is adequate for stage IE or pure MALT lymphoma when staging is performed after radical gastrectomy.
A 2015 review notes that historically surgery was the leading treatment for primary gastric MALT lymphoma, but that discovery of H. pylori involvement, new drugs, chemotherapy protocols, and monoclonal antibodies have raised the effectiveness of conservative treatment. Conformal radiotherapy techniques have also allowed fine results, especially with combined chemo-radiotherapy protocols. However, the review states that complete remission cannot be achieved in all cases and that more research is required.
A 2013 retrospective survey of 57 patients with non-gastric MALT lymphoma reported a median age of 58 years. Common presenting sites included lungs and upper respiratory tract (29.8%), intestinal tracts (28.1%), orbital and ocular adnexal (12.3%), and salivary glands (14.0%). Stage I–II disease was present in 61.4% of patients, stage III–IV in 38.6%. Regimens included surgery alone, chemotherapy alone, surgery followed by chemotherapy or chemoradiotherapy. The complete response rate was 66.0% and the overall response rate 85.7%. At a median follow-up of 52 months, the 5-year overall survival was 91.6% and the 5-year progression-free survival was 77.7%. The 5-year survival rates for surgery, chemotherapy, surgery plus chemotherapy, and surgery plus chemotherapy plus radiotherapy groups were 87.5%, 100.0%, 90.2%, and 100.0%, respectively, with no statistically significant differences. The 5-year progression-free survival for the four groups were 62.3%, 80.0%, 90.2%, and 75.0%. The recurrence rate with surgery alone was relatively high at 22.3%.
A 2008 case report describes a 61-year-old woman with a MALT lymphoma of the conjunctiva who had a second relapse after two previous total resections. Staging gave no hint of metastases. The patient was referred for chemotherapy with an R-CHOP regime. A 2018 case report describes a 59-year-old man diagnosed with gastric MALT lymphoma who presented with gastric perforation one month after diagnosis. Emergency gastric perforation repair and jejunostomy was performed; the patient recovered and was preparing for combined chemotherapy. The authors of that report state that early diagnosis and timely appropriate chemotherapy is of great importance. What remains missing are prospective trials that directly compare modern conservative approaches (antibiotics, chemotherapy, radiotherapy, monoclonal antibodies) against each other and against surgery in clearly stratified patient groups, particularly for non-gastric sites and for relapsed disease.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Annals of Surgery · 1998 · 48 citations · open access
The Role of Radical Gastrectomy With Systematic Lymphadenectomy for the Diagnosis and Treatment of Primary Gastric Lymphoma
AbstractOBJECTIVE: We evaluated the therapeutic efficacy of radical gastrectomy for primary B-cell lymphoma of the stomach and attempted to identify patients who could be adequately treated with surgery alone. SUMMARY BACKGROUND DATA: Several recent gastric lymphoma reports have discussed the therapeutic benefits of various treatment strategies for stage IE and IIE lymphoma. However, few studies have been based on patients accurately staged by systematic lymphadenectomy with subsequent pathologic examination. METHODS: A retrospective study was performed to evaluate the survival and biologic behavior of lesions in 60 patients with gastric lymphoma who were treated by radical gastrectomy alone. Tumors were classified according to the histopathologic concept of mucosa-associated lymphoid tissue (MALT)-derived lymphoma. RESULTS: A low histopathologic grade was associated with a significantly lower incidence of nodal metastasis (p = 0.07) and less extensive infiltration of the gastric wall (p < 0.005) despite larger tumor size. A 5-year survival rate of >95% was attained with surgery alone for MALT lymphoma and for true stage IE lymphoma diagnosed by pathologic examination of up to N2 lymph nodes routinely performed after radical gastrectomy. CONCLUSIONS: Surgery alone is adequate treatment for stage IE or pure MALT lymphoma, provided that the staging is performed after radical gastrectomy.
Journal of Thoracic Disease · 2022 · 7 citations · open access
A systematic review and meta-analysis of thymic mucosa-associated lymphoid tissue lymphoma
AbstractBackground: Mucosa-associated lymphoid tissue (MALT) lymphoma of the thymus is a rare disease. The present meta-analysis aims at accumulating current evidence to explore the clinical characteristics, treatments, and prognoses of thymic MALT lymphoma. Methods: We searched seven databases for studies published between the start date of database establishment and September 15, 2021. We included studies of patients with histological diagnoses and excluded those without data specifically on thymic MALT lymphoma. The quality was analyzed using an assessment tool. All data were tabulated. Pooled proportion was obtained using random-effects model. Statistical analysis was performed on R statistic software. Results: Overall, 52 case reports and 13 case series were eligible. The quality of case reports was inferior to that of case series in terms of selection (P<0.001). Based on the analysis of patients in the case reports, age, gender, concurrent diseases, and tumor size did not differ between limited-stage and advanced-stage cases. Surgery is the mainstay to treat thymic MALT lymphoma. The surgical approach and extent did not influence the occurrence of events. Patients at Ann Arbor stage I were prone to not receiving postoperative therapy (P=0.011), though it may not reduce the occurrence of events (P=0.637). The five-year overall survival (OS) rate and five-year progression-free survival (PFS) rate were 97.2% and 88.4%, respectively. Patients with advanced-stage disease were more likely to suffer events (P=0.009). Conclusions: Thymic MALT lymphoma is an extremely rare disease with a favorable prognosis. Currently available evidence is insufficient to draw solid judgments about treatment and prognosis. However, patients may benefit if thymectomy is chosen as the primary treatment. In some patients, lymph node sampling or dissection should be considered. In addition, if the patient is at an advanced-stage, postoperative therapy should be considered.
Leukemia & lymphoma/Leukemia and lymphoma · 2005 · 6 citations
Very good partial response in a patient with MALT-lymphoma of the lung after treatment with low-dose thalidomide
AbstractPulmonary MALT lymphoma is a rare disease entity and generally follows an indolent clinical course. Due to scarce information from randomized prospective trials, no standardized therapy protocols exist. Besides irradiation and chemotherapy, novel biological agents such as the anti CD20-antibody rituximab and thalidomide constitute a promising new approach. In this report we demonstrate the case of a 52-year-old male patient with extra-intestinal MALT lymphoma of the lung. After 10 months of treatment with low dose thalidomide (100mg/d), very good partial response of the intrapulmonary lesions was achieved.
Perforation caused by gastric mucosa associated lymphoid tissue lymphoma
AbstractRATIONALE: Gastric mucosa-associated lymphoid tissue (MALT) lymphoma is the most common and best-studied extranodal marginal zone lymphoma of the MALT. It is characterized by an indolent clinical course and excellent survival compared with other malignant tumor. Complications such as obstruction, perforation or bleeding are rarely observed. The treatment strategy is still controversial. PATIENT CONCERNS: A 59-year-old man, who had been diagnosed with MALT lymphoma by gastroscopy and biopsy one month before, came to the hospital for a sudden onset of abdominal pain after breakfast. DIAGNOSES: MALT lymphoma; gastric perforation. INTERVENTIONS: Emergency surgery. OUTCOMES: Gastric perforation repair and jejunostomy was performed. The patient recovered well and is preparing for combined chemotherapy. LESSONS: This case report illustrates the challenges in diagnosis and treatment of MALT lymphoma. We discussed the particularity of its clinical characteristics, treatment strategies and prognosis combined with literature review, and we think that early diagnosis and timely appropriate chemotherapy is of great importance.
[Analyses of clinical features and outcomes of 57 patients with non-gastric MALT lymphoma].
AbstractOBJECTIVE: To further understand the clinical features of non-gastric mucosa-associated lymphoid tissue (MALT) lymphoma and investigate its suitable treatment. METHODS: A retrospective survey of 57 non-gastric MATL lymphoma patients pathologically confirmed in our hospital from 1999 to 2011. RESULTS: The median age was 58 years (range 14-86 years). Common presenting sites of non-gastric MALT lymphoma included lungs and upper respiratory tract (17 patients, 29.8%), intestinal tracts (16 patients,28.1%), orbital and ocular adnexal (7 patients, 12.3%), and salivary glands (8 patients, 14.0%). Stage Ⅰ-Ⅱdisease presented in 35 patients (61.4%), stage Ⅲ-Ⅳ disease in 22 patients (38.6%). A total of 26 patients had nodal involvement and 7 patients multiple organ involvement. Regimens included surgery alone, chemotherapy alone, surgery followed by chemotherapy or chemoradiotherapy. The complete response (CR) rate was 66.0% and the overall response rate 85.7%. At a median follow-up of 52 months, the 5-year overall survival (OS) and the 5-year progression free survival (PFS) were 91.6% and 77.7%, respectively. The 5-year survival rate of surgery, chemotherapy, surgery+chemotherapy, surgery + chemotherapy + radiotherapy groups were 87.5%, 100.0%, 90.2% and 100.0%, respectively, without significant differences. The 5-year PFS of the four groups were 62.3%, 80.0%, 90.2% and 75.0% respectively. CONCLUSION: Non-gastric MALT lymphoma is characterized by disseminated onset, favorable response to treatments and good outcomes. There is no statistically significant difference in the overall survival of the various treatments. But the recurrence rate of surgery alone is relatively high (22.3%).
Klinische Monatsblätter für Augenheilkunde · 2008 · 1 citations
Re-Re-Rezidiv eines MALT-Lymphoms der Bindehaut
AbstractBACKGROUND: The MALT lymphoma (mucosa-associated lymphoid-like tissue lymphomas) is a rare entity and belongs to the low-grade non-Hodgkin (NHL) lymphomas. In 8 % of cases it arises in the conjunctiva. In some cases a MALT lymphoma of the conjunctiva is misdiagnosed as chronic conjunctivitis. Mostly a MALT lymphoma of the conjunctiva can be cured by radiation and has a good prognosis. CASE REPORT: A 61-year-old female presented to our hospital because of alteration of the conjunctiva and worsening of her general condition. Symptoms were fatigue, lassitude, night sweat, loss of appetite and gastrointestinal problems. The medical history revealed treatment for a MALT lymphoma 4 years previously and a relapse 3 years previously. Both were resected totally. Staging at those times gave no hint for metastases. The ophthalmological examination showed an adherent prominence with conjunctival injection of the right eye at 10 - 11 o'clock. It corresponded to the localisation of the primary tumour in 2002 and the relapse in 2003. Slit lamp and fundoscopic examinations only revealed a cataracta incipiens. CLINICAL COURSE: To confirm the diagnosis a biopsy was done. The histological examination demonstrated a relapse of the MALT lymphoma. Staging gave no hint for metastases. The patient was referred to the oncological unit for chemotherapy (R-CHOP regime). CONCLUSION: This case shows that a relapse of the MALT lymphoma may arise although the previous tumour and its relapse were resected totally. In patients with tumours in their medical history suffering from unspecific discomfort, a biopsy should may be be considered despite the lack of apparent macroscopic findings.
Journal of New Medical Technologies · 2015 · 0 citations
Primary gastric malt lymphoma - modern treatment approaches
AbstractMain idea of this article is to make a short overview of modern MALT lymphoma treatment approaches. Historically, surgery was the leading treatment modality. Discovery of H.pylori involvement, invention of new drugs and chemotherapy protocols, wide use of monoclonal antibodies, significantly raised the effectiveness of conservative treatment. Routine use of CT scanning, invention of conformal, precise radiotherapy techniques allowed to achieve fine radiotherapy treatment results, especially in the case of combined chemo – radiotherapy protocols. That is why nowadays conservative treatment plays more significant role. However, complete remission cannot be achieved in all the cases. More research is required and thorough analyze of advantages and disadvantages of every technique and their combinations.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
